Innovent Biologics Placement - Momentum Is Very Strong but past Deals Have Been Mixed
Innovent Biologics Inc (1801 HK) is looking to raise about U$600m to fund its clinical trials and product licensing and possible M&A. This will be...
429 Views
Pre-IPO Bio-Thera Solutions - Insights on Pipeline and the Competitive Landscape
This article summarized the insights on major products of Bio-Thera Solutions in the pipeline and related competitive landscape with other key...
336 Views
China Healthcare: Macro Themes
This Insight summarizes the takeaways from a recent China healthcare industry conference. There is much talk of pressures on the industry, but...
472 Views
Harbour Biomed IPO: Positive Thoughts in Brief
This Insight includes a brief analysis of Harbour Biomed and its proposed listing on the HKEX. We like the deal at the price range offered.
341 Views
Simcere Pharmaceutical IPO: Valuation Insights
We think that an attractive PEG valuation and solid cornerstone support makes Simcere tempting at the proposed pricing range
470 Views